DIFFERENTIAL DIAGNOSTIC ROLE OF ANEMIA AND INFLAMMATORY MARKERS IN PATIENTS WITH RHINOSINUSITIS AGAINST THE BACKGROUND OF GRANULOMATOSIS WITH POLYANGIITIS
DOI:
https://doi.org/10.57231/j.ejohns.2025.4.4.008Keywords:
granulomatosis with polyangiitis, rhinosinusitis, anemia, complete blood count, erythrocyte sedimentation rate, systemic vasculitis, diff erential diagnosisAbstract
Objective: To assess the diff erential-diagnostic value of anemia and in$ ammatory markers in patients with
rhinosinusitis on the background of granulomatosis with polyangiitis (GPA). We examined three clinical groups of GPA
patients and a control group with isolated chronic rhinosinusitis. All patients underwent standard ENT examination and
complete blood count; parameters were compared according to disease stage and presence of systemic involvement.
GPA-associated rhinosinusitis was characterized by normocytic anemia, markedly increased erythrocyte sedimentation
rate, reactive leukocytosis and dynamic changes in platelet count, which were signi# cantly more pronounced than
in chronic rhinosinusitis without vasculitis. Combined alterations in hemoglobin level, ESR, leukocytes and platelets
correlated with ANCA positivity and renal involvement and allowed early suspicion of systemic vasculitis. We conclude
that integrated analysis of anemia and in$ ammatory markers represents a simple laboratory tool that helps to distinguish
GPA-related rhinosinusitis from common ENT pathology and should be incorporated into routine diagnostic algorithms.
References
Hunter RW, Welsh N, Farrah TE, Gallacher PJ. ANCAassociated vasculitis. BMJ. 2020;369:m1070.
Austin K, Janagan S, Wells M, et al. ANCA associated vasculitis subtypes: recent insights and future perspectives.J In$ amm Res. 2022;15:2567–2582.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCAassociated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30–47.
KDIGO ANCA Vasculitis Work Group. KDIGO 2024 clinical practice guideline for the management of ANCAassociated vasculitis. Kidney Int. 2024;105(3S):S71–S116.
Delvino P, La Rocca G, et al. Systemic vasculitis: one year in review 2025. Clin Exp Rheumatol. 2025;43(Suppl.).
Drouzas K, Gougourelas I, Tsiakalos A, et al. Current understanding of the pathogenesis of ANCA-associated vasculitis. Life (Basel). 2025;15(5):756.
Almeida S, Neves PM, Domingues VDS. Pathogenesis and biomarkers in ANCA-associated vasculitis. Vessel Plus. 2021;5:27.
Morris AD, Rowbottom AW, Martin FL, Woywodt A, Dhaygude AP. Biomarkers in ANCA-associated vasculitis: potential pitfalls and future prospects. Kidney360. 2021;2(4):586–597.
Scurt FG, Micheroli R, Bünzli S, et al. Old known and possible new biomarkers of ANCA-associated vasculitis. Rheumatol Int. 2022;42:1017–1030.
Shumnalieva R, Kolarov Z, Stoilov R, et al. New biomarkers for systemic necrotizing vasculitides. J Clin Med.
;13(8):2264.
Marvisi C, Arioli D, Gallelli L, et al. Biomarkers in ANCAassociated vasculitis: clinical utility, pitfalls and their
role in the outcomes assessment. Front Immunol. 2025;16:1616837.
Lee LE, Yoon T, Chung J, Ha JW, Park Y B, Lee S W. Serum glial # brillary acidic protein can predict cross-sectional vasculitis activity by re$ ecting renal involvement in patients with ANCA-associated vasculitis. Medicina. 2024;60(10):1639.
Yoon T, Ha JW, Park Y B, Lee S W. Serum Wnt3A in antibodyassociated vasculitis: associations with disease activity and renal outcomes. Clin Exp Rheumatol. 2025;43.
